Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Completed · Phase 1/Phase 2

Conditions studied: Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma

In brief

The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Key facts

Study ID

NCT02807844

Run by

Novartis Pharmaceuticals

People needed

141

Starts

2016-06-29

Expected to finish

2020-06-04

Last updated by the study team

2021-08-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Dana Farber Cancer Center — Boston, Massachusetts, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• The West Clinic — Germantown, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Novartis Investigative Site — Wilrijk, Belgium
• Novartis Investigative Site — HUS, Finland
• Novartis Investigative Site — Saint-Herblain, France
• Novartis Investigative Site — Frankfurt, Germany
• Novartis Investigative Site — Ulm, Germany
• Novartis Investigative Site — Hong Kong, Hong Kong
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Koto Ku, Tokyo, Japan
• Novartis Investigative Site — Seoul, South Korea
• Novartis Investigative Site — Seoul, South Korea
• Novartis Investigative Site — Valencia, Valencia, Spain
• Novartis Investigative Site — Madrid, Spain
• Novartis Investigative Site — Chur, Switzerland
• Novartis Investigative Site — Geneva, Switzerland
• Novartis Investigative Site — Zurich, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.